Filing Flows

Filing Flows › 8-K events › Adial Pharmaceuticals

Adial Pharmaceuticals: departure or appointment of directors and officers

Form 8-K filed Oct 28, 2026 · items 5.02, 5.03, 5.07, 7.01

CEO changesAdial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

What the filing says

The Board of Directors (the “ Board ”) of Azora Therapeutics, Inc., formerly known as Adial Pharmaceuticals, Inc. (the “ Company ”), appointed Matthew Davidson, Ph.D. as President and Chief Executive Officer of the Company, on October 28, 2026 (the “ Effective Date ”). Davidson will also remain a member of the Board.

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Item 5.03: +0.1% next session across 5,869. Item 5.07: 0.0% next session across 16,815. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.